Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

The End of the Beginning: COVID-19 Vaccines & Other Conundrums

Philip Seo, MD, MHS  |  Issue: January 2021  |  December 9, 2020

In phase 1b, essential workers will take priority. This includes teachers, emergency responders, corrections officers and those who work in the food industry, agriculture, utilities and transportation, none of whom can avoid contact with other people. In phase 1c, priority will go to adults who are older than 65 years or have comorbid conditions that place them at risk for poor outcomes from COVD-19. Together, these phases represent another 250 million Americans. Again to put this in perspective, the U.S. government has currently purchased enough vaccine from Pfizer and Moderna to vaccinate 100 million Americans.12 Total.

What makes these decisions even more weighty is the implied ethical decisions. If we wish to limit mortality, the elderly should be vaccinated first. If we wish to limit disease spread, then vaccinating essential workers makes more sense. But people who work in childcare, elder care and public transportation have even higher rates of developing COVID-19 than other essential workers; shouldn’t they hop to the front the list?13 On the other hand, vaccinating teachers first may allow us to open schools earlier than would have been possible otherwise. The incarcerated pose a particularly sticky issue: It is impossible to socially distance in prison. Where should they fall in line?

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

There are also many unknowns: How effective will these vaccines be in immunocompromised or immunosuppressed patients? More specifically, will the RNA-based vaccines cause lupus patients to flare by inducing a type I interferon response? And how good are these vaccines at preventing the asymptomatic infections that are responsible for much of the pandemic? The AstraZeneca vaccine reduces SARS-CoV-2 RNA-positivity among asymptomatic patients, but what about the Moderna and Pfizer vaccines? We just don’t know.14

Of course, none of this may matter if no one agrees to get vaccinated.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

In November, the Pew Research Center conducted a survey of 12,648 Americans and found that 60% would be willing to be vaccinated against SARS-CoV-2.15 In most ways, that’s good news. First, we assume that interest in the vaccine will climb as friends and neighbors continue to be hospitalized with COVID-19 in ever escalating numbers. Second, an additional 21% of those surveyed would probably be willing to receive the vaccine; they just want more information. And they want to see others go first. That brings us to 81%, which is around what we would need to achieve herd immunity; if four out of every five Americans agree to be vaccinated, we may be able to hamper the spread of SARS-CoV-2 just enough to tame the pandemic.

Page: 1 2 3 4 5 6 | Single Page
Share: 

Filed under:OpinionRheuminationsSpeak Out Rheum Tagged with:COVID-19

Related Articles

    Vax Hesitancy? Myths & Facts for Patients

    December 16, 2021

    Although more than 189,300,000 eligible Americans are fully vaccinated against SARS-CoV-2 as of Oct. 18, 2021, vaccine hesitancy persists.1 The U.S. Centers for Disease Control and Prevention (CDC), citing data from the U.S. Census Bureau’s Household Pulse Survey collected between May 26 and June 7, 2021, reports that in some U.S. counties—particularly in the Southeast…

    Vaccine Hesitancy: Wariness Is Rare, But There’s a Wider Worry About COVID Vaccines’ Efficacy in Some Populations

    July 6, 2021

    Hesitancy about COVID-19 vaccination persists nationwide, although it varies among regions and sociodemographic groups.

    Anze Furlan / SHUTTERSTOCK.COM

    How Immunosuppression May Affect COVID-19 Vaccine Response

    June 13, 2021

    Although we can expect to learn much more, preliminary data are now available on the potential safety and effectiveness of COVID-19 vaccines in rheumatology patients. The picture is likely to be nuanced, with not all types of immuno­suppressive treatments having identical impacts on vaccine response. Rheumatologists should use caution in interpreting early reports, while continuing…

    ACR Convergence 2020

    ACR Convergence 2020: Progress Toward COVID-19 Vaccines

    November 11, 2020

    ACR CONVERGENCE 2020—A scientific session on Sunday, Nov. 8, focused on vaccine prospects in COVID-19. Dan Barouch, MD, PhD, director of the Center for Virology and Vaccine Research at Beth Israel Deaconess Medical Center and the William Bosworth Castle Professor of Medicine at Harvard Medical School in Boston, shared his insights about vaccine development across…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences